Welcome to Institute of Biochemistry II
Perspectives in Molecular Medicine Lectures
|22th Nov 2013
Structure of HOIP catalytic core solved
In collaboration with Katrin Rittinger at the MRC-NIMR in London, the Dikic group solved another molecular puzzle about the formation of specific Ubiquitin chains. In the current issue of Nature, they report the crystal structure of the catalytic core of HOIP, the critical enzymes involved in forming linear (Met1-linked) Ubiquitin chains. These chains are important regulators of cellular signalling, and knowing the molecular structure of the complexes involved is an important step forward to understanding how these pathways control innate immunity and inflammation.
Link to nature publication
|19th Nov 2013
Who's most cited of them all?
In its recent issue, Laborjournal (LJ) publishes a citation analysis in the field of cell biology covering the period from 2007 to 2010. Instead of asking the mirror, LJ searched the database "Web of Science" for authors based in Germany, Austria and Switzerland. Amongst the Top 5: IBC2 director Ivan Dikic with 1886 citations of 35 articles. One article from the Dikic lab made it under the Top 10 of most cited articles: the report about a role for the protein NBR1 in autophagy , published by Kirkin and collaborators 2009 in the journal Molecular Cell.
Link to article in Laborjournal
Link to Kirkin et al paper
|30th Oct 2013
Bless the team work
It took years to develop, and the input of scientists from five countries: BLESS, a novel technology for mapping DNA breaks by next generation sequencing. The resulting publication in Nature Methods by Crosetto, Dikic, Rowicka, and many colleagues is now featured by Laborjournal.
Link to LJ article in German
Link to original artcle
Link to BLESS website
|22th Oct 2013
LOEWE program Ub-Net recruitment drive
The LOEWE program Ubiquitin-Networks is a newly established interdisciplinary research network at the Goethe University which is led by Ivan Dikic.
The network recently received funding and is looking to recruit 1 Junior Group Leader, 1 Postdoc, and 12 PhD students. Deadline for applications is 7th November. Read full advertisement
|16th Oct 2013
New Group Leader
The IBCII welcomes Dr. Andreas Ernst from University of Toronto as independent group leader.
The research of his newly established protein engineering group is focussed on generating intracellular tools to study various signaling pathways.
|25th Aug 2013
Award-winning cancer reseacher from Croatia
|8th Jan 2013
Professor Ivan Dikic receives Ernst Jung Prize for medicine
8th January 2013. The Jung Foundation for Science and Research announced that Frankfurt professor Ivan Dikic will receive the Ernst Jung Prize 2013 for his groundbreaking work in understanding the role of Ubiquitin in cellular signal regulation. The prize is awarded with 150,000 euro and will be presented at a ceremony on 3rd May in Hamburg.
|6th Dec 2012
Leibniz Prize 2013 for Frankfurt professor Ivan Dikic.
In recognition of his groundbreaking work in decrypting the Ubiquitin code, Ivan Dikic is to receive the Gottfried Wilhelm Leibniz Prize 2013, Germany's most prestigious scientific award. The award is funded and presented by the German Research Foundation (DFG). It is the research prize with the highest endowment worldwide and comes with a grant of 2.5 M Euro.
|16th Oct 2012
Dr.Krishnaraj Rajalingam, an Emmy Noether Fellow from IBCII has been selected to be a PLUS3fellow of the Boehringer Ingelheim Foundation.
BIF will fund his research on Inhibitors of Apoptosis (IAPs) with a generous support of 825000 euros for the next three years.
|1st August 2012
2013 ASBMB William C. Rose Award goes to BMLS Director Ivan Dikic.
The Award honors the pioneering work of Ivan Dikic in understanding the Ubiquitin code, and his efforts in training and education of young scientists.
|18th June 2012
Seeing Ubiquitin chains in cells.
An international team of scientists led by IBCII director Ivan Dikic developed specific Ubiquitin biosensors for in vivo application. This approach might mark a major technical breakthrough in detection of Ubiquitin signals in living cells. It is published in today's online issue of Molecular Cell.
|10th May 2012
A novel mechanism regulating SUMO-dependent protein networks.
The covalent attachment of the ubiquitin-like modifier SUMO to proteins serves an important mechanism for the control of protein-protein interactions. This is generally mediated via recognition of a SUMO-conjugate by an interaction partner that contains a specific SUMO interaction module, termed SIM (SUMO interaction motif). A major question is how the dynamics of SUMO/SIM interactions are regulated. Recent work done by Rebecca Ullmann in Stefan Muller's group together with co-workers from the Lombardi Cancer Center in Washington now uncovered an acetyl-dependent switch that determines the selectivity and dynamics of SUMO-SIM interactions (Molecular Cell, online May 10, 2012). In this context they show that acetylation of SUMO within a basic interface prevents binding to SIMs in PML, Daxx, and PIAS. One the other hand, acetyl-SUMO specifically binds to the Bromodomain of the co-activator p300. This acetyl-dependent switch of SUMO-mediated protein interactions attenuates SUMO-regulated gene silencing and affects the assembly of PML nuclear bodies. This work thus unravels a novel interplay of post-translational modifications that expands the regulatory repertoire of SUMO signaling.
Ullmann R, Chien C D, Avantaggiati M L, Muller S (2012) An acetylation switch regulates SUMO-dependent protein interaction networks, Mol Cell, online May 10, 2012, DOI 10.1016/j.molcel.2012.04.006
Read more about SUMO Signaling Group
|23th January 2012
Novel mechanism regulating cell shape and migration unveiled.
Cell shape and migration are controlled by RhoGTPases, a family of small GTPases whose activation is controlled by nucleotide binding. Rac1 is an important member of this family and
Read the full article
Read the HYS highlight
Read the research highlight from Nat. Rev. Mol. Cell Bio.
Read the faculty of 1000 evaluation
Read more about Krishna Rajalingam
|24th October 2011
Interview with Prof. Dr. Dr. Ivan Dikic, director of the Frankfurt Institute of Molecular Life Sciences (FMLS)
If you were granted one wish for the advancement of your research projects, what would this be?
Well, I've always valued and emphasized a creative atmosphere. It not only means being surrounded by intelligent people, but also having enough time
Read whole story here
Read more about Ivan Dikic
|13th September 2011
ERC Starting Grant awarded to Dr. Christian Behrends:
The ERC approved funding for his proposal on Xenophagy and bacterial avoidance (XABA). Briefly, microbial pathogens that successfully parasitize eukaryotic cells have evolved to evade autophagic microbial defenses (xenophagy) and subvert the host autophagic responses for their own survival and/or growth.
Whole story in Press release
More about Christian Behrends
|26th May 2011
New defense mechanism against Salmonella elucidated: infection with Salmonella, epithelial cells can get rid of the unwanted invader by a process called autophagy. In today's issue of the journal Science, an international group of scientists around IBC2 director Ivan Dikic describes how selectivity is achieved in this process.
Read full article or in Press release
|19th April 2011
A new Emmy Noether Fellow at the IBCII: Dr. Christian Behrends received the prestigious Emmy Noether Research Fellowship by the DFG. His independent group will be funded for three years with a perspective two3 years extension. The mammalian
More about Christian Behrends
|31st March 2011 - A step towards understanding chronic dermatitis: An international team of scientists led by IBCII director Ivan Dikic discovered a novel role for the protein SHARPIN in immune signalling.|
Read full article
| 1st Feb 2011 - IBCII is pleased to announce its new W2: Prof. Stefan Müller is appointed W2 professor in biochemistry at IBCII and will be an independant group leader for SUMO signaling group.
More about Stefan Müller
|1st Nov. 2010 - New group leader
Dr. Christian Behrends from Harvard Medical School in Boston will join IBCII as an independant group leader. He will establish the Autophagy signaling group.
More about Christian Behrends